Dompe U.s. Inc.
San Mateo, CA Part of Dompe' Farmaceutici SPA
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Corporate family
-
-
Parent
-
Parent
- SAM.gov registration date
- Physical address
- 400 S El Camino Real # 400, San Mateo, CA 94402, USA
- Website
- dompe.com
- Founded
- 1940
- Employees
- 251-1K
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $241,160 |
| FY2025 | $475,550 |
| FY2024 | $115,843 |
| FY2023 | $280,103 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Veterans Affairs | $241,160 |
Contract vehicles
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Botanix SB Inc. | Phoenix, AZ | 325412 Pharmaceutical Preparation Manufacturing |
| Jazz Pharmaceuticals, Inc. | Menlo Park, CA | 325412 Pharmaceutical Preparation Manufacturing |
| Agios Pharmaceuticals, Inc. | Cambridge, MA | 325412 Pharmaceutical Preparation Manufacturing |
| Amneal Pharmaceuticals Of New York, LLC | Medford, NY | 325412 Pharmaceutical Preparation Manufacturing |
| CSL Behring L.L.C. | King of Prussia, PA | 325412 Pharmaceutical Preparation Manufacturing |
About the company
Dompe U.S. Inc., a foreign-owned pharmaceutical manufacturer headquartered in San Mateo, California, supplies branded ophthalmic pharmaceuticals to the Department of Veterans Affairs as a prime contractor exclusively through GSA Federal Supply Schedule and blanket purchase agreement vehicles, with no subcontract footprint.
The vendor's entire federal portfolio consists of delivery orders and blanket purchase agreements for Oxervate (cenegermin-bkbj) 0.002% ophthalmic solution, a specialty pharmaceutical used to treat neurotrophic keratitis. Dompe holds a $84.083 million Federal Supply Schedule contract under FSS-61-IB (Drugs, Pharmaceuticals & Hematology Related Products) awarded June 1, 2026, with ultimate completion May 31, 2031, which serves as the primary vehicle for delivery orders across the VA system. The vendor also holds a single-award blanket purchase agreement valued at $49,717.65, effective through February 18, 2027, issued by the VA National Acquisition Center. All 44 awards in the source data are prime contracts; Dompe operates without subcontractors. Delivery orders placed under these vehicles have ranged from approximately $18,000 to $224,082 per order, with recent awards including a $166,465.92 order from Veterans Integrated Service Network 5 on April 28, 2026, for direct shipment of Oxervate to beneficiary homes, and a $159,096.48 emergency order from VISN 12 on February 13, 2025.
Customer concentration is extreme and monolithic. The Department of Veterans Affairs accounts for 100% of the vendor's federal awards across 11 distinct VISNs and the VA National Acquisition Center. By potential value, VISN 12 dominates with $89.5 million across ten awards (87% of total portfolio value), while VISN 5 and VISN 20 contribute $704 thousand and $571 thousand respectively across smaller volume orders. The concentration pattern reflects Dompe's single-product, single-customer posture: the vendor is a specialized supplier of a branded ophthalmic pharmaceutical to a healthcare system with multiple regional acquisition points.
Activity shows growth through 2025 before flattening. Awards per year increased from two in 2023 to twelve in 2025, then dropped to two year-to-date in 2026. However, combined potential value remains substantial at $103.9 million across all awards, though only $2.3 million (2%) has been obligated to date, reflecting the indefinite-delivery nature of the GSA schedule and BPA vehicles and the episodic, demand-driven ordering pattern characteristic of VA pharmaceutical procurement. No recompete cliff is present; the vendor's two primary vehicles extend through 2027 and 2031 respectively.
The vendor competes under full-and-open, non-set-aside procurement exclusively. All 44 awards carry no set-aside designation and are placed through government-wide GSA vehicles open to unrestricted competition. Dompe's market access depends entirely on GSA schedule approval and inclusion on the VA's preferred supplier list for this specialty pharmaceutical rather than on SBA certifications or small-business set-asides.
Quick answers
Is Dompe U.s. Inc. registered in SAM.gov?
Yes. Dompe U.s. Inc.'s SAM.gov registration is active through August 5, 2027.
What is Dompe U.s. Inc.'s CAGE code?
Dompe U.s. Inc.'s CAGE code is 89P46, and its Unique Entity ID (UEI) is ECCDSKQAN2J3.
Which contract vehicles does Dompe U.s. Inc. hold?
Dompe U.s. Inc. holds a place on 1 federal contract vehicle: FSS-61-IB.
How much has Dompe U.s. Inc. received in federal contracts?
Federal contracts obligated $475,550 to Dompe U.s. Inc. in fiscal year 2025 and $1,112,656 in fiscal years 2023 through 2027.
How does Dompe U.s. Inc. rank among federal contractors?
Dompe U.s. Inc. ranked #96 in NAICS 325412 in FY2025.
What is Dompe U.s. Inc.'s most recent federal award?
Dompe U.s. Inc.'s most recent federal contract award is Patient medication of oxercate .002% for direct shipment to the patients home (36C24526N0555), from Veterans Integrated Service Network 5 (VHA), on April 28, 2026.
On GovTribe
See Dompe U.s. Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Funding analysis by agency, NAICS and set-aside
- Similar vendors